Purpose

The bill aims to prevent health plans from requiring patients with neurological conditions to go through a step therapy process before accessing an FDA-approved drug that is on the plan’s formulary. It ensures that if a drug is FDA-approved and aligns with clinical practice guidelines, the patient should not be forced to try other therapies first.

Key terms defined

• Neurological condition: a disorder affecting neurological function, whether from injury or illness.
• Step therapy protocol: a process that requires trying certain drugs in a specified sequence before others.
• Clinical practice guideline: a set of evidence-based recommendations used to guide patient care (as defined in related Minnesota law).
• FDA-approved indication: the official medical use for which the drug has FDA approval.
• Health plan and prescription drug formulary: the health plan’s covered drugs list to which the rule applies.
• Enrollee: a person covered by the health plan.

Main provisions

• Prohibition on step therapy for neurological conditions: A health plan that covers treatment for neurological conditions may not require an enrollee to follow a step therapy protocol if the drug is FDA-approved and on the plan’s formulary and used in a way that matches the FDA-approved indication and clinical practice guideline.
• Coverage consistency: The prohibition applies only when the FDA-approved indication for the drug and the clinical practice guideline support its use for the enrollee’s neurological condition.

Significance and effects

• Removes barriers to access: Patients with neurological conditions should not face forced-step decisions when choosing effective, FDA-approved medications that are already on the plan’s formulary.
• Aligns coverage with guidelines and labeling: Decisions must be consistent with FDA indications and respected clinical practice guidelines, reducing delays or denials tied to step therapy in this medical area.
• Creates a new legal standard within Minnesota Statutes Chapter 62Q.

Practical examples (illustrative)

• If a patient has a neurological condition and there are FDA-approved drugs on their health plan’s formulary that are appropriate for their condition according to the FDA labeling and prescribed clinical guidelines, the plan cannot require trying a first-line, less-preferred drug before approving the FDA-approved option.
• If the drug is FDA-approved for the condition and is listed on the formulary, the plan should cover it without imposing a step-therapy sequence.

Relationship to existing law

• Establishes a new prohibition within Minnesota Statutes Chapter 62Q regarding step therapy specifically for neurological conditions, clarifying that certain evidence-based and regulatory standards must be met before any step therapy requirements can apply.

Relevant terms step therapy protocol; neurological condition; health plan; FDA-approved; prescription drug formulary; clinical practice guideline; enrollee; indication; coverage.